Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omidubicel for Severe Aplastic Anemia and Hypo-plastic MDS
NCT03173937Phase 2Recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jun 2017
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 2 trial of omidubicel in aplastic anemia and myelodysplastic syndrome (MDS), sponsored by National Heart, Lung, and Blood Institute. Started Jun 2017; status: recruiting.
02
Drugs
omidubicel
03
Conditions
aplastic anemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03173937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173937.